Am J Perinatol 2007; 24(4): 207-213
DOI: 10.1055/s-2007-976546
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Safety of Prolonged Indomethacin Therapy

Ashlyn H. Savage1 , Brenna L. Anderson1 , 2 , Hyagriv N. Simhan1 , 2
  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Pittsburgh, Pennsylvania
  • 2Division of Maternal-Fetal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Further Information

Publication History

Publication Date:
19 April 2007 (online)

Preview

ABSTRACT

The purpose of this study was to describe the fetal and newborn safety profile of prolonged indomethacin treatment during pregnancy. A retrospective cohort of 124 pregnant women treated with indomethacin was used to assess the outcomes of oligohydramnios, constriction of the ductus arteriosus, and composite neonatal morbidity. Eight patients (6.5%) developed ductal constriction and nine patients (7.3%) developed oligohydramnios. Composite morbidity occurred in 36 neonates (29%). Ductal constriction, oligohydramnios, and composite morbidity were not associated with duration of therapy, gestational age at start or stop of therapy, time between dosing and delivery, or dose regimen. Prolonged indomethacin therapy rarely is associated with ductal constriction and oligohydramnios.

REFERENCES

Hyagriv N SimhanM.D. M.S.C.R. 

Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital

300 Halket Street, Pittsburgh, PA 15213